English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, May 23, 2024
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
Wednesday, May 22, 2024
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
Wednesday, May 15, 2024
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Monday, May 13, 2024
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
Thursday, April 18, 2024
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Wednesday, April 17, 2024
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売
Wednesday, April 3, 2024
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Monday, April 1, 2024
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Thursday, August 5, 2021
エーザイ、第37回企業広報賞「企業広報大賞」を受賞

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575